RichardSamuelFinnMD
Oncology • Santa Monica, CAAssistant Professor, Medicine, UCLA School of Medicine
Are you Dr. Finn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2020 Santa Monica Blvd
Suite 580
Santa Monica, CA 90404Phone+1 310-829-5471Fax+1 310-829-5471
Summary
- Dr. Richard Finn, MD is an oncologist in Santa Monica, California. He is currently licensed to practice medicine in California. He is affiliated with UCLA Medical Center-Santa Monica and Ronald Reagan UCLA Medical Center.
Education & Training
David Geffen School of Medicine at UCLAClass of 1997
Certifications & Licensure
CA State Medical License 1999 - 2026- CA State Medical License 1999 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsTiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a...Richard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, Daneng Li, Adam M Burgoyne
The Lancet. Oncology. 2025-02-01 - 5 citationsTransarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a...Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Guohong Han, Hailan Lin
Lancet. 2025-01-18 - Correlation of Needle Biopsy-Acquired Histopathologic Grade of Hepatocellular Carcinoma with Outcomes after Thermal Ablation.Jason Chiang, Steven S Raman, Abinaya Ramakrishnan, Pedram Keshavarz, James W Sayre
Journal of Vascular and Interventional Radiology. 2025-01-01
Press Mentions
Anti-TIGIT Shows Promise in Unresectable Liver CancerJanuary 22nd, 2025- Novartis Announces Tislelizumab Demonstrated Efficacy and Tolerability in First-Line Advanced Liver Cancer in Phase III TrialSeptember 10th, 2022
- PALOMA-2: No Overall Survival Benefit Reported with Palbociclib/Letrozole in Advanced Breast CancerJuly 26th, 2022
- Join now to see all
